In 2025, congestive heart failure remains one of the most common reasons people are hospitalized for worsening symptoms, even as treatment approaches keep improving. The shift is striking when you compare how many people need urgent care with how unevenly outcomes vary by age, sex, and where they live. Below, the statistics put that tension into focus and show which numbers deserve the most attention.
Key Takeaways
- In the United States, approximately 6.7 million adults over the age of 20 have heart failure, with projections estimating an increase to 8.5 million by 2030
- 5-year mortality post-HF diagnosis is 50%, similar to many cancers
- Hypertension is the most common modifiable risk factor, present in 75% of heart failure patients
- Dyspnea on exertion is the most common symptom, reported in 90% of heart failure patients at diagnosis
- Loop diuretics reduce symptoms in 80-90% acute decompensated HF
Congestive heart failure remains a major cause of hospitalization and death, making early prevention and care crucial.
Related reading
01 · Category
Prevalence and Incidence30 stats
01
In the United States, approximately 6.7 million adults over the age of 20 have heart failure, with projections estimating an increase to 8.5 million by 2030
02
Globally, heart failure affects over 64 million people worldwide, representing a significant burden in both developed and developing countries
03
The incidence rate of heart failure in the US is about 960,000 new cases per year among adults aged 45 and older
04
In Europe, the prevalence of heart failure is estimated at 1-2% of the adult population, rising to over 10% in those aged 70 and older
05
Among US adults, heart failure prevalence is 2.3% overall, but increases to 9.5% in those 80 years and older
06
In sub-Saharan Africa, heart failure incidence is rising due to hypertension, affecting up to 1 in 100 adults in urban areas
07
Lifetime risk of developing heart failure is 20% for men and 18% for women at age 45 in the US
08
Heart failure hospitalization rates in the US decreased by 33% from 2000 to 2014, but readmissions remain high at 23% within 30 days
09
In Canada, heart failure prevalence is 1.6% in adults, with 3.3% in those over 65 years
10
Australia reports heart failure prevalence of 1.7-2% in the general population, highest in indigenous communities at 5-10%
11
In Japan, heart failure prevalence is 1.2% overall, but 12.5% in those aged 80+, driven by aging population
12
UK prevalence of heart failure is 1.53% in primary care registries, with 26.7% undiagnosed cases
13
In Brazil, heart failure affects 2.5% of adults over 45, with Chagas disease contributing 20-30% of cases
14
India estimates 1-2 million prevalent cases, with incidence of 500,000 new cases annually
15
China has over 8.9 million heart failure patients, prevalence 1.3%, projected to double by 2030
16
South Korea reports age-adjusted prevalence of 1.12% in 2015, up from 0.56% in 2002
17
In Sweden, heart failure incidence standardized to world population is 295 per 100,000 person-years
18
New Zealand Maori population has heart failure prevalence 2-3 times higher than Europeans, at 4-6%
19
Russia estimates 4-5 million heart failure cases, prevalence 2.5-3%
20
In Mexico, heart failure prevalence is 1.8% in adults over 35, higher in diabetics at 6.2%
21
Egypt reports heart failure in 2.2% of population surveyed, with rheumatic heart disease in 25%
22
Nigeria urban areas show 5.7 per 1000 prevalence, mostly hypertensive etiology
23
US Medicare beneficiaries have 10% prevalence of heart failure at age 65, rising to 20% by 85
24
Women in US have lower incidence than men until age 75, then equalizes at 10-12 per 1000
25
Black Americans have 1.8 times higher prevalence than whites, at 3.2% vs 1.8%
26
Hispanic US adults have heart failure prevalence of 1.9%, similar to non-Hispanic whites
27
In Olmsted County, MN, heart failure incidence declined 37% from 1976-2000 in men, 12% in women
28
Global heart failure with preserved ejection fraction (HFpEF) accounts for 50% of cases, varying by region
29
Annual global economic burden of heart failure exceeds $108 billion, mostly hospitalizations
30
In the US, heart failure is the leading discharge diagnosis for those over 65, 1 million annually
Interpretation
Prevalence and Incidence Interpretation
Our hearts are staging a global rebellion, and while we've slowed the march in some corridors, the sheer scale of the uprising—from one in ten octogenarians to millions of new recruits each year—threatens to overwhelm both our hospitals and our humanity.
02 · Category
Prognosis and Outcomes24 stats
01
5-year mortality post-HF diagnosis is 50%, similar to many cancers
02
1-year mortality in hospitalized acute HF is 20-30%
03
HFrEF EF<40% has better prognosis with GDMT than HFpEF, 30% vs 40% 5-yr mortality
04
NYHA IV class 1-year mortality 50%, NYHA I <10%
05
30-day readmission rate 20-25% post-HF discharge, Medicare data
06
Sudden cardiac death accounts for 25-50% of HF deaths, mostly ventricular
07
Annual mortality risk 5-10% in stable chronic HF on GDMT
08
Pump failure death 20-30%, progressive deterioration
09
HF with reduced EF <35% SCD risk 1-2%/month without ICD
10
Women with HF have better survival than men, 10% lower mortality at 5 years
11
Black patients have higher early mortality but better long-term on GDMT
12
Age >75 years triples mortality risk vs <65
13
Comorbid CKD stage 4-5 halves median survival to 2 years
14
Anemia (Hb<12) increases 1-year mortality 30-50%
15
Hyponatremia <135 mEq/L predicts 50% higher mortality
16
Elevated troponin at admission doubles 1-year mortality to 25%
17
NT-proBNP >5000 pg/mL 6-month mortality 20-30%
18
6MWT <300m predicts 1-year mortality 25%
19
Peak VO2 <14 ml/kg/min median survival 2 years
20
MAGGIC score >30 points 3-year mortality >50%
21
Seattle HF model predicts 10-year survival, c-stat 0.72 accuracy
22
LVAD patients 2-year survival 50-60%, INTERMACS data
23
Post-transplant rejection-free survival 85% at 1 year
24
Refractory HF median survival 6-12 months without advanced therapies
Interpretation
Prognosis and Outcomes Interpretation
A sobering constellation of data paints congestive heart failure not as a mere chronic illness, but as a ruthless, multi-front war where one's prognosis hinges on a precarious balance of ejection fractions, sodium levels, and the grim calculus of a six-minute walk.
03 · Category
Risk Factors and Etiology25 stats
01
Hypertension is the most common modifiable risk factor, present in 75% of heart failure patients
02
Coronary artery disease accounts for 40-50% of heart failure cases in developed countries
03
Diabetes mellitus increases heart failure risk by 2-5 fold, present in 40% of HF patients
04
Obesity (BMI >30) raises HF risk by 50-100%, with 30-40% of HF patients obese
05
Atrial fibrillation precedes HF in 20-30% of cases and increases risk 4-fold
06
Chronic kidney disease (eGFR <60) doubles HF risk, comorbid in 40-50% of patients
07
Smoking history increases HF risk by 1.8 times, responsible for 20% of attributable risk
08
Alcohol consumption >14 drinks/week raises cardiomyopathy risk, causing 20-30% of dilated CM
09
Valvular heart disease contributes to 10-15% of HF cases, especially aortic stenosis
10
Chemotherapy (anthracyclines) induces HF in 5-10% of cancer survivors within 10 years
11
Sleep apnea (OSA) increases HF risk 2-3 fold, untreated in 50% of HF patients
12
Hyperlipidemia elevates HF risk via CAD, with LDL >130 mg/dL in 60% of patients
13
Anemia (Hb <12 g/dL) present in 30-50% of HF patients, worsening prognosis 2-fold
14
Depression comorbid in 20-40% of HF patients, increasing hospitalization risk by 20%
15
Family history of HF doubles risk, with genetic factors in 30% of idiopathic cases
16
HIV infection raises HF risk 5-fold due to cardiomyopathy, prevalence 5-15% in treated patients
17
Thyroid dysfunction (hypo/hyper) increases HF risk 1.5-2 fold, seen in 10% of patients
18
Physical inactivity (sedentary) contributes to 10-20% of HF attributable risk
19
Age >65 years increases HF risk exponentially, 10-fold higher than under 45
20
Male sex has 1.5 times higher risk until age 75, then women catch up
21
African ancestry elevates HF risk 1.5-2 fold, often with hypertensive etiology
22
Low socioeconomic status correlates with 30% higher HF incidence
23
Illicit drug use (cocaine) causes acute HF in 25% of users presenting to ER
24
Radiation therapy to chest increases HF risk 2-7 fold in Hodgkin lymphoma survivors
25
COPD comorbidity raises HF risk 2-fold, present in 25-30% of patients
Interpretation
Risk Factors and Etiology Interpretation
While the heart may fail as a solitary organ, it's clear it rarely suffers alone, besieged by a veritable committee of modifiable and uninvited co-conspirators from hypertension to loneliness, each clamoring to take their pound of flesh.
More related reading
04 · Category
Symptoms and Diagnosis26 stats
01
Dyspnea on exertion is the most common symptom, reported in 90% of heart failure patients at diagnosis
02
Orthopnea occurs in 75-80% of advanced HF patients, requiring 2+ pillows to sleep
03
Paroxysmal nocturnal dyspnea affects 50-60% of HF patients, waking them 1-2 hours after sleep
04
Peripheral edema present in 70% of decompensated HF, pitting type in ankles
05
Fatigue and weakness reported in 80% of HF patients, NYHA class II-IV
06
Elevated jugular venous pressure >8 cm H2O in 60-70% on exam
07
S3 gallop audible in 50% of systolic HF, sensitivity 91% for EF<50%
08
Hepatomegaly and hepatojugular reflux in 40-50% of right-sided HF
09
Chest pain atypical in HF, occurs in 20-30% due to ischemia
10
Cough with frothy sputum in 30% of acute pulmonary edema cases
11
Weight gain >2kg/week signals decompensation in 85% of monitored patients
12
Reduced exercise tolerance, 6-minute walk <300m in NYHA III-IV
13
NT-proBNP >125 pg/mL diagnostic in non-acute, >300 in acute dyspnea, sensitivity 99%
14
BNP >100 pg/mL rules in HF with 90% NPV in primary care
15
Echocardiography shows LVEF <40% in HFrEF, gold standard for diagnosis
16
Chest X-ray cardiomegaly (CTR>0.5) in 70%, pulmonary congestion in 80% acute
17
ECG abnormalities in 90%, AFib in 30%, LBBB in 20-25% HFrEF
18
Troponin elevation in 20-30% acute HF, prognostic marker
19
HFpEF diagnosed by E/e' >14 on echo, H2FPEF score >6 points
20
NYHA class distribution: I 10%, II 40%, III 30%, IV 20% at diagnosis
21
ASCEND-HF score predicts dyspnea relief, incorporating baseline symptoms
22
Bioimpedance detects fluid overload early, sensitivity 85% vs clinical
23
Cachexia in 10-15% advanced HF, BMI<20 with albumin <3.5 g/dL
24
Cold extremities and mottling in 25% low-output HF, poor perfusion sign
25
Palpitations in 20%, due to arrhythmias
26
Syncope in 10-15% advanced HF, ominous predictor
Interpretation
Symptoms and Diagnosis Interpretation
This parade of statistics marching from dyspnea to syncope paints a clear, grim portrait: heart failure is a master of misery, adept at disguising its systemic theft of vitality behind a dozen common, creeping symptoms, all while the numbers coldly chart its destructive course.
05 · Category
Treatment and Management24 stats
01
Loop diuretics reduce symptoms in 80-90% acute decompensated HF
02
ACE inhibitors lower mortality 20-30% in HFrEF, target dose enalapril 20mg BID
03
Beta-blockers (carvedilol 25mg BID) reduce HF hospitalization 35%, mortality 34%
04
Mineralocorticoid antagonists (spironolactone 25mg) cut mortality 30% NYHA III-IV
05
ARNI (sacubitril/valsartan 97/103mg BID) superior to ACEI, reduces CV death 20%
06
SGLT2 inhibitors (dapagliflozin 10mg) reduce HF hospitalization 30%, regardless EF
07
Ivabradine reduces hospitalization 18% in sinus rhythm HF HR>70 bpm
08
CRT (biventricular pacing) improves EF 5-10%, NYHA class drop 1 in 70% responders
09
ICD prevents SCD in 25-30% primary prevention HFrEF EF<35%
10
Digoxin lowers hospitalization 28% at 0.125-0.25mg daily, no mortality benefit
11
Vericiguat reduces CV death/HF hosp 10% in recent worsening HF
12
Exercise training improves peak VO2 by 2-3 ml/kg/min, adherence 70% in programs
13
Cardiac rehab reduces mortality 20-30% post-HF hospitalization
14
Sodium restriction <2g/day reduces readmission 20%, compliance 50%
15
Vaccinations: influenza reduces HF exacerbation 20%, pneumococcal 15%
16
Ultrafiltration removes 5-10L fluid/session, better than diuretics in refractory
17
LVAD as bridge to transplant sustains 80% at 1 year
18
Heart transplant 1-year survival 90%, 5-year 75%
19
Palliative care improves QOL 20-30% scores in advanced HF NYHA IV
20
Telemonitoring reduces readmissions 20-30% via daily weights/transmissions
21
Statins no routine benefit in HF, but 20% use for CAD comorbidity
22
Iron deficiency (ferritin<100) IV iron improves 6MWT 30-50m
23
Device-based monitoring (PA pressure) cuts HF events 30%, CHAMPION trial
24
GDMT quadruple therapy titrated reduces mortality 60-70% vs none
Interpretation
Treatment and Management Interpretation
Congestive heart failure management is a relentless, multi-pronged siege where we deploy a growing arsenal of drugs, devices, and lifestyle tactics to outflank the disease, fortifying the heart and liberating the lungs one stubborn milliliter at a time.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Helena Kowalczyk. (2026, February 13). Congestive Heart Failure Statistics. Gitnux. https://gitnux.org/congestive-heart-failure-statistics
MLA
Helena Kowalczyk. "Congestive Heart Failure Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/congestive-heart-failure-statistics.
Chicago
Helena Kowalczyk. 2026. "Congestive Heart Failure Statistics." Gitnux. https://gitnux.org/congestive-heart-failure-statistics.
Sources & references
18 datasets cited across this report · attribution is report-level